Standard BioTools announced its financial results for the fourth quarter and full fiscal year ended December 31, 2024. The company reported a total revenue of $46.7 million for Q4 2024, with a net loss of $34.1 million and an adjusted EBITDA loss of $18.4 million, showing improvements compared to the previous year.
Full year 2024 pro forma combined revenue reached $175.1 million.
The company achieved a 17% Full Year reduction in pro forma operating loss and a 33% year-over-year improvement in adjusted EBITDA.
An additional $10 million in operational cost reductions were realized, bringing the total synergies to $90 million over 12 months.
Standard BioTools maintains a strong balance sheet with $295 million in cash, cash equivalents, restricted cash, and short-term investments, with no material debt at year-end 2024.
For fiscal year 2025, Standard BioTools expects revenue to be in the range of $165 million to $175 million.
Visualization of income flow from segment revenue to net income